1. Home
  2. LFT vs SNTI Comparison

LFT vs SNTI Comparison

Compare LFT & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lument Finance Trust Inc.

LFT

Lument Finance Trust Inc.

HOLD

Current Price

$0.69

Market Cap

36.6M

Sector

Real Estate

ML Signal

HOLD

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$0.36

Market Cap

31.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LFT
SNTI
Founded
2012
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.6M
31.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
LFT
SNTI
Price
$0.69
$0.36
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
266.6K
313.3K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
18.49%
N/A
EPS Growth
N/A
77.31
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$668.15
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.49
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.64
$0.33
52 Week High
$2.37
$2.88

Technical Indicators

Market Signals
Indicator
LFT
SNTI
Relative Strength Index (RSI) 28.99 25.54
Support Level N/A N/A
Resistance Level $1.40 $1.18
Average True Range (ATR) 0.05 0.04
MACD -0.00 0.01
Stochastic Oscillator 17.75 10.91

Price Performance

Historical Comparison
LFT
SNTI

About LFT Lument Finance Trust Inc.

Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

Share on Social Networks: